ficlatuzumab ficlatuzumab ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers. ficlatuzumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targethgfclinical dataatc codenoneidentifierscas number1174900-84-5 nchemspidernoneunii77e89833tgkeggd10123 nchemical and physical dataformulac6446h9954n1718o2026s46molar mass145409.30 g·mol−1 ny (what is this?) (verify) it is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-met receptor signaling cascade. ficlatuzumab was developed by aveo pharmaceuticals. in may 2012, aveo released results of a phase ii clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive asian patients with non-small cell lung cancer.